Skip to main content
Skip to main content
CJMB logo

Callan JMB Inc. (CJMB) Stock Analysis

Educational signal · not a buy or sell recommendation · How to read this

$2.26 $0.00 (+1.33%) |Weak · 17
Callan JMB Inc. (CJMB) bottom line: Bearish Lean — our Council read (21/100) and AI Score (17/100) broadly agree. Strongest signal: Momentum · Biggest watch-out: Growth Durability.Educational signal, not a buy or sell recommendation. Compare sector peers → · Read the method →
Vol: 53.3K| 52-wk range: $0.65 – $5.61

Beta 0.90: the stock has moved about 10% less than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated May 4, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Callan JMB Inc. (CJMB) trades at $2.26 with MoonshotScore 17/100 (Grade F). Callan JMB Inc. specializes in thermal management logistics solutions for the life sciences sector, focusing on frozen shipping. Sector: Industrials.

Price as of Sep 11, 2026 · Last analyzed: May 4, 2026
Callan JMB Inc. specializes in thermal management logistics solutions for the life sciences sector, focusing on frozen shipping. The company operates through its subsidiary, Coldchain Technology Services, LLC, and has been in operation since 2006.

Analyst Coverage for CJMB: CJMB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CJMB against Industrials peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.

Watch the CJMB film Every key number, told as a short cinematic story — just press play. ~2 min
Council Score · Weighted Average of 3 Disciplines
Bearish Lean 21/100 · F

CJMB: 3/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.

How is this calculated? →
MoonshotScore · Five-pillar engine · 17/100
Business Quality
Negative Is this a genuinely good business?
Financial Safety
Negative Could this blow up on me?
Valuation
Negative Am I paying a fair price?
Growth Durability
Negative Is the growth real and likely to last?
Momentum
Moderate Is the market already moving on this?

Strongest side: Momentum (7/10, Moderate). Weakest side: Growth Durability (0/10, Negative).

Legends Council · 5 Legends + Moon AI

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Klarman-style lens (simulated)Seth Klarman
Unfavorable read
Moon AI lens (model)
Unfavorable read
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Negative
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →
The lenses are modelled on the published principles of the investors named. We are not affiliated with them, they have not endorsed this, and it is not their opinion of this stock.

Why this analysis is different

  • A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
  • An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
  • Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Callan JMB Inc. (CJMB) Industrial Operations Profile

CEOWayne Williams
Employees19
HeadquartersSpring Branch, TX, US
IPO Year2025

Callan JMB Inc. is a specialized provider of thermal management logistics solutions for the life sciences industry, focusing on the critical needs of frozen shipping for sensitive biological materials, thereby positioning itself as a key player in a growing niche market.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: May 4, 2026

What Is the Investment Thesis for CJMB?

AI-written as of May 4, 2026 — figures and tone reflect the data available then, not today's score.

Callan JMB Inc. operates in a niche market with significant growth potential driven by the increasing demand for life sciences logistics solutions. The global market for cold chain logistics in pharmaceuticals is expected to grow at a CAGR of 16.7% from 2021 to 2028, presenting a substantial opportunity for Callan JMB to expand its services. The company's gross margin of 36.8% indicates a solid pricing strategy and operational efficiency, although its current negative profit margin of -139.2% highlights the need for improved cost management and revenue generation. As the life sciences sector continues to expand, particularly in personalized medicine and biopharmaceuticals, Callan JMB's expertise in frozen shipping and thermal management logistics will be critical. Investors should monitor the company's ability to leverage its existing capabilities while addressing its financial challenges to unlock value.

Based on FMP financials and quantitative analysis

CJMB Key Highlights

AI-written as of May 4, 2026 — figures and tone reflect the data available then, not today's score.

Market Cap of $0.01B reflects a small but specialized player in the logistics sector.

  • Gross margin of 36.8% indicates a competitive pricing strategy within the niche market.
  • Negative profit margin of -139.2% highlights current financial challenges that need addressing.
  • Operational efficiency supported by a small team of 26 employees allows for agile responses to client needs.
  • Beta of 0.90 suggests lower volatility compared to the overall market.

Who Are CJMB's Competitors?

CJMB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
COLD Americold Realty Trust, Inc. $14.12 +3.29% $4.03B
WERN Werner Enterprises, Inc. $38.59 -0.77% $2.31B 625-pillar
CHRW C.H. Robinson Worldwide, Inc. $152.96 +0.36% $18.0B
UPS United Parcel Service, Inc. $99.69 -0.28% $84.7B 585-pillar
FDX FedEx Corporation $313.31 +0.48% $74.1B 655-pillar
JBHT J.B. Hunt Transport Services, Inc. $267.83 +0.01% $25.2B 725-pillar
EXPD Expeditors International of Washington, Inc. $189.32 +0.54% $24.8B 895-pillar
XPO XPO Logistics, Inc. $182.34 -1.04% $21.4B 535-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CJMB's Key Strengths?

Niche focus on thermal management logistics for life sciences.

  • Strong expertise in handling sensitive biological materials.
  • Established subsidiary, Coldchain Technology Services, enhances service offerings.

What Are CJMB's Weaknesses?

Small employee base limits scalability and operational capacity.

  • Negative profit margin indicates potential financial instability.
  • Limited brand recognition compared to larger competitors.

What Could Drive CJMB Stock Higher?

Expansion of service offerings to include new temperature-sensitive products by Q4 2026.

  • Development of strategic partnerships with biotech firms to enhance market presence.
  • Continuous improvement in operational efficiencies to address negative profit margins.

What Are the Key Risks for CJMB?

Financial-distress signal — its Altman Z-Score of -8.88 sits in the distress zone (elevated bankruptcy risk).

  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
  • Economic downturns could reduce demand for logistics services in the life sciences sector.
  • Intense competition from larger logistics providers could pressure pricing and margins.
  • Regulatory changes could introduce new compliance costs for logistics operations.

What Are the Growth Opportunities for CJMB?

  • Growth opportunity 1: The global cold chain logistics market is projected to reach $500 billion by 2028, driven by the increasing demand for temperature-sensitive pharmaceuticals. Callan JMB can capitalize on this trend by expanding its service offerings and geographic reach, particularly in regions with emerging biotech industries.
  • Growth opportunity 2: The rise of personalized medicine is creating a surge in demand for specialized logistics services. Callan JMB's focus on frozen shipping for sensitive biological materials positions it to benefit from this trend, as more healthcare providers seek reliable logistics partners to handle complex supply chains.
  • Growth opportunity 3: As regulatory requirements for the transportation of biological materials tighten, companies will increasingly seek compliant logistics providers. Callan JMB's established expertise in cold chain logistics can serve as a competitive advantage, allowing it to attract clients who prioritize compliance and reliability.
  • Growth opportunity 4: The expansion of e-commerce in pharmaceuticals is creating new logistics challenges and opportunities. Callan JMB can leverage its capabilities in thermal management to develop tailored solutions for online pharmacies and biotech firms looking to deliver temperature-sensitive products directly to consumers.
  • Growth opportunity 5: The increasing prevalence of global health crises, such as pandemics, has underscored the importance of efficient logistics in the life sciences sector. Callan JMB can enhance its service offerings to support rapid response efforts, thereby positioning itself as a critical partner in emergency logistics.

What Are CJMB's Competitive Advantages?

  • Specialized expertise in thermal management logistics for the life sciences sector.
  • Established relationships with clients in the pharmaceutical and biotech industries.
  • Compliance with stringent regulations governing the transportation of biological materials.

What Does CJMB Do?

Founded in 2006 and headquartered in Spring Branch, Texas, Callan JMB Inc. operates primarily through its subsidiary, Coldchain Technology Services, LLC, delivering essential thermal management logistics solutions tailored for the life sciences industry. The company has carved out a niche in the logistics sector by focusing on frozen shipping solutions, which are critical for transporting sensitive materials such as personalized medicine, cell therapies, stem cells, vaccines, and various biological commodities. Over the years, Callan JMB has evolved to meet the increasing demands of the life sciences sector, which requires precise temperature control and specialized handling to ensure the integrity of its products. The company also provides services for perishable non-pharmaceutical packaging and technical logistics support, enhancing its service portfolio. With a small team of 26 employees, Callan JMB is agile and able to adapt quickly to the specific needs of its clients, which include pharmaceutical firms, research institutions, and biotechnology companies. This focus on specialized logistics solutions positions Callan JMB as a critical partner in the supply chain for life sciences, where the stakes of product integrity are exceptionally high.

What Products and Services Does CJMB Offer?

  • Provide thermal management logistics solutions for the life sciences industry.
  • Specialize in frozen shipping for sensitive biological materials.
  • Offer logistics services for personalized medicine and biopharmaceuticals.
  • Deliver technical services and packaging solutions for perishable goods.
  • Operate through its subsidiary, Coldchain Technology Services, LLC.
  • Focus on compliance with industry regulations for transporting sensitive materials.

How Does CJMB Make Money?

  • Generate revenue through logistics services tailored to the life sciences sector.
  • Charge clients for specialized packaging and thermal management solutions.
  • Offer consulting and technical services to enhance logistics efficiency.
  • Leverage expertise in compliance to attract clients in regulated industries.

What Industry Does CJMB Operate In?

The integrated freight and logistics industry is witnessing significant transformation, particularly in the life sciences sector, driven by advancements in biopharmaceuticals and personalized medicine. The cold chain logistics market is projected to grow substantially, with increasing demand for temperature-sensitive products necessitating specialized logistics solutions. Callan JMB Inc. fits into this landscape as a focused provider of thermal management logistics, catering specifically to the unique requirements of the life sciences industry. With the global cold chain logistics market expected to reach $500 billion by 2028, Callan JMB's specialized services position it well to capture a share of this expanding market.

Who Are CJMB's Key Customers?

  • Pharmaceutical companies requiring reliable frozen shipping solutions.
  • Biotechnology firms focused on personalized medicine and cell therapies.
  • Research institutions needing logistics support for sensitive biological materials.
Model self-rating on this text: 65% (not a measure of the evidence) Updated: May 4, 2026

Research confidence

High 85/100

Broad, current evidence sits behind this analysis.

  • Scored on 91% of our measures
  • Price is current
  • Latest filing 28 days ago
  • No analyst coverage

Why 17?

Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.

What is helping

  • +0.53 Volatility vs the market (Financial Strength)
  • +0.50 Gross profit per dollar of assets (Business Quality)
  • +0.36 3-month price trend (Momentum)

What is holding it back

  • -0.78 Return on invested capital (Business Quality)
  • -0.78 Return on assets (Business Quality)
  • -0.78 Operating margin (Business Quality)

Risk penalties applied

  • -1.89 Bankruptcy-risk score in the distress zone
  • -2.00 Loss-making with negative retained earnings

Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →

MoonshotScore History

Recorded daily since 2026-08-23 · 19 snapshots

2026-08-23 16
2026-08-26 16
2026-08-29 16
2026-09-01 18
2026-09-04 18
2026-09-07 17
2026-09-10 17

What changed?

The grade moved from 16 to 17 (+1).

What moved it up or down:

  • +1 Business Quality
  • +1 Valuation

Held back by:

  • -7 Momentum
  • -4 Financial Safety

Over the same 18 days the stock moved -9.6%.

Company Profile

Callan JMB Inc. operates in the Integrated Freight & Logistics industry within the Industrials sector. It is headquartered in Spring Branch, US. The company is led by CEO Wayne Williams. CJMB has traded publicly since 2025.

F-Score 3/9

Financial Health

Callan JMB Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.88 places it in the distress zone, a signal of elevated financial risk.

CJMB Valuation & Market Position

Relative to its peer group, CJMB's quantitative score of 17/100 is below the peer average of 67/100.

Quarterly Financial Performance: Callan JMB Inc.

Revenue for Callan JMB Inc. came in at $1.4M during Q2 FY2026, a 24.4% improvement versus the preceding quarter. The company recorded a net loss of $1.2M, with diluted EPS of $-0.22. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Industrials. Across the four most recent quarters, CJMB averaged $-0.50 in diluted EPS.

Net buying

Insider Activity

The most recent 12 insider filings for Callan JMB Inc. break down as 0 sales and 12 purchases. On net that is roughly 103K shares acquired (about $164K) — insiders putting money in tends to read as conviction.

CJMB Financials

Fundamental Snapshot

Revenue Growth (FY)
-12.8%
Net Income Growth (FY)
-247.3%
EPS Growth (FY)
-109.2%
Return on Equity (TTM)
-285.4%
Current Ratio
2.0

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Niche focus on thermal management logistics for life sciences.
  • Strong expertise in handling sensitive biological materials.
  • Established subsidiary, Coldchain Technology Services, enhances service offerings.
  • Upcoming: Expansion of service offerings to include new temperature-sensitive products by Q4 2026.

Bear Case

  • Small employee base limits scalability and operational capacity.
  • Negative profit margin indicates potential financial instability.
  • Limited brand recognition compared to larger competitors.
  • Potential: Economic downturns could reduce demand for logistics services in the life sciences sector.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · September 2026

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q2 FY2026 $1M -$1M -$0.22
Q1 FY2026 $1M -$3M -$0.59
Q4 FY2025 $1M -$3M -$0.58
Q3 FY2025 $1M -$3M -$0.61

Q2 FY2026 · filed 14 Aug 2026 · SEC EDGAR →

Based on FMP financials and quantitative analysis

CJMB Latest News

CJMB Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CJMB.

Price Targets

Wall Street price target analysis for CJMB.

CJMB MoonshotScore

17/100

What does this score mean?

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. CJMB scores 17/100 (Grade F): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Leadership: Wayne Williams

CEO

Wayne Williams has been leading Callan JMB Inc. since its inception in 2006. With a background in logistics and supply chain management, he has extensive experience in the life sciences sector. Williams holds a degree in Business Administration and has previously worked in various roles within the logistics industry, focusing on temperature-sensitive products.

Track Record: Under Wayne's leadership, Callan JMB has established itself as a specialized provider in thermal management logistics, successfully navigating the complexities of the life sciences supply chain.

Common Questions About CJMB (Industrials)

What does the AI Score mean for CJMB?

CJMB holds an AI Score of 17/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Callan JMB Inc. specializes in thermal management logistics solutions for the life sciences sector, focusing on frozen shipping.

Is CJMB a good stock?

Stock Expert AI does not rate CJMB buy, sell or hold. Callan JMB Inc. carries a MoonshotScore of 17/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.

How does Callan JMB Inc. compare to competitors in its industry?

Callan JMB Inc. differentiates itself by focusing exclusively on thermal management logistics for the life sciences sector, catering to the unique needs of transporting sensitive biological materials. While larger competitors like Americold Realty Trust and C.H.

What are the key factors to evaluate for CJMB?

Callan JMB Inc. (CJMB) holds a MoonshotScore of 17/100 (low). Callan JMB Inc. operates in a niche market with significant growth potential driven by the increasing demand for life sciences logistics solutions. Not financial advice.

How frequently does CJMB data refresh on this page?

CJMB's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.

What has driven CJMB's recent stock price performance?

Callan JMB Inc. (CJMB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Niche focus on thermal management logistics for life sciences. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CJMB overvalued or undervalued right now?

Callan JMB Inc. (CJMB) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of CJMB?

Yes, most major brokerages offer fractional shares of Callan JMB Inc. (CJMB) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track CJMB's earnings and financial reports?

Callan JMB Inc. (CJMB) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for CJMB earnings announcements.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated MoonshotScore as of
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Data is based on available information as of 2026-05-04. Financial metrics may vary with market conditions.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

More Stocks We Cover